Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936811 | 1.00 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL2936815 | 1.00 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL1030224 | 0.98 | HCRTR2 (0.39) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL2038232 | 0.98 | HCRTR2 (0.39) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL1030223 | 0.98 | HCRTR2 (0.39) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL1761274 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL9154429 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| Acetic Acid SCHEMBL21617326 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| Hydrochloric Acid SCHEMBL5195834 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL9162631 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333626-A | Phenyl pyrrolidine compounds and uses thereof | 湖北生物医药产业技术研究院有限公司 | 2020-06-26 | — | — | CN | disclosed |
| WO-2020125627-A1 | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2020-06-25 | — | — | WO | disclosed |
| US-20060264494-A1 | Heterocyclic amide derivatives which process glycogen phorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| US-20060199966-A1 | Indol-2-amides as glycogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2006-09-07 | — | — | US | disclosed |
| EP-1660448-A1 | INDOL-2-AMIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1656136-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005019172-A1 | INDOL-2-AMIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018637-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264494-A1 | Heterocyclic amide derivatives which process glycogen phorylase inhibitory activity | PYGL, PYGM, G6PC1 | HCRTR2 4123/4885HCRTR1 3382/4885L3MBTL1 1798/4885 |
| US-20060199966-A1 | Indol-2-amides as glycogen phosphorylase inhibitors | PYGL, PYGM, GYS1 | HCRTR2 2220/4885HCRTR1 1978/4885L3MBTL1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.